In a xenograft (PDX) model of triple-negative breast cancer (TNBC), the combination of irinotecan (TOP1 inhibitor) and ATR inhibitor VE-822 significantly improved tumor growth inhibition and inhibited CHK1 phosphorylation in SLFN11-negative tumors, overcoming the limitations of single-drug therapy (58). This evidence concerns the gene ATR and neoplasm.